STOCK TITAN

Ideaya Biosciences - IDYA STOCK NEWS

Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.

IDEAYA Biosciences Inc. (IDYA) is a clinical-stage biotechnology leader advancing precision oncology therapies through synthetic lethality and biomarker-driven approaches. This news hub provides investors and researchers with timely updates on IDYA's innovative pipeline, strategic collaborations, and scientific advancements in targeting cancer vulnerabilities.

Access authoritative reporting on clinical trial progress, regulatory milestones, and research breakthroughs. Our curated collection includes press releases detailing IDEAYA's novel small molecule therapies, molecular diagnostic developments, and partnerships advancing personalized cancer treatments.

Key updates cover therapeutic candidates targeting DNA damage response pathways, tumor microenvironment innovations, and biomarker validation studies. Stay informed about IDEAYA's pioneering work in matched oncology therapies through verified financial filings and scientific disclosures.

Bookmark this page for consolidated access to essential IDYA developments, carefully sourced to support informed analysis of the company's position in the precision medicine landscape. Check regularly for new updates on clinical data readouts and strategic initiatives shaping the future of targeted cancer treatment.

Rhea-AI Summary
IDEAYA Biosciences, Inc. announces pricing of public offering of common stock and pre-funded warrants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
-
Rhea-AI Summary
IDEAYA Biosciences announces plans for a public offering of up to $125.0 million of its common stock and pre-funded warrants. The offering is subject to market conditions and the underwriters have a 30-day option to purchase additional shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
-
Rhea-AI Summary
IDEAYA Biosciences presents clinical data on darovasertib in metastatic uveal melanoma at ESMO 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.54%
Tags
Rhea-AI Summary
IDEAYA Biosciences announces the publication of abstract for a proffered paper session at ESMO 2023, presenting clinical data from Phase 2 trial of darovasertib in combination with crizotinib in metastatic uveal melanoma (MUM).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.6%
Tags
-
Rhea-AI Summary
IDEAYA Biosciences initiates Phase 2 expansion of darovasertib and crizotinib combination in GNAQ/11 metastatic cutaneous melanoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
-
Rhea-AI Summary
IDEAYA Biosciences selects a Werner Helicase Inhibitor Development Candidate and announces an Investor R&D Day
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
Rhea-AI Summary
IDEAYA Biosciences grants stock options to newly hired employee
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
-
Rhea-AI Summary
IDEAYA Biosciences receives Fast Track designation from the FDA for IDE161 in breast cancer treatment, expanding its development program. Phase 1 expansion shows preliminary tumor shrinkage in multiple patients with HRD solid tumors. Program updates expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
Rhea-AI Summary
IDEAYA Biosciences initiates Phase 1 expansion of IDE161 in HRD solid tumors, demonstrating preliminary tumor shrinkage and target engagement. Clinical program updates expected in H2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
Ideaya Biosciences

Nasdaq:IDYA

IDYA Rankings

IDYA Stock Data

1.50B
86.63M
1.04%
109.56%
10.5%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO